GI Innovation, Inc. (358570.KQ)
Seoul, KR
GI Innovation, Inc. specializes in the research and creation of biopharmaceutical products. Its current developmental portfolio features drug candidates G-101, G-102, G-301, and G-108. Founded by Jang Myoung-ho on July 19, 2017, the company's main operations are situated in Seoul, South Korea.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| -8.93% | +2.48% | -10.89% | -10.29% | -22.94% | -14.52% | -18.24% | +25.10% | +43.01% | +43.01% | +43.01% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 0 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
-
Revenue growth Biotechnology: +1.6%+23,943.9% ★ Q1'26: -100.0% (vs Q1'25)
-
EPS growth Biotechnology: +29.7%+50.7% ★ Q1'26: +26.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%-724.9%
-
EBIT margin Biotechnology: +0.0%-713.6%
-
ROIC Biotechnology: -16.1%-50.9% Q1'26: -56.9% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+20.0% Q1'26: +29.9% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×-0.13× Q1'26: -0.05× (vs Q1'25)
| Metric |
Dec 2023 actual |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|---|
| Revenue |
5.32B
est: 11.50M (+46,150.9%)
|
24.28M
est: 198.00M (-87.7%)
|
5.84B
est: 63.00M (+9,166.8%)
|
| EBITDA |
-51.33B
est: -11.50M (-446,250.7%)
|
-54.92B
est: -198.00M (-27,635.8%)
|
-38.67B
est: -63.00M (-61,286.4%)
|
| EBIT |
-54.66B
est: -11.50M (-475,202.3%)
|
-48.26B
est: -198.00M (-24,273.7%)
|
-41.66B
est: -63.00M (-66,031.6%)
|
| Net Income |
-55.50B
est: -80.91B (+31.4%)
|
-58.78B
est: 304.90B (-119.3%)
|
-35.13B
est: -47.38B (+25.9%)
|
| SGA |
15.15B
est: 312.34M (+4,750.0%)
|
2.70B
est: 5.38B (-49.8%)
|
3.91B
est: 1.71B (+128.3%)
|
| EPS |
-1,257.87
est: -1,551.25 (+18.9%)
|
-1,127.58
est: 4,871.00 (-123.1%)
|
-556.15
est: -757.00 (+26.5%)
|
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-29 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-28 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-27 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-26 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 4/5 | 1/5 | 1/5 |
| 2026-05-22 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-21 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-20 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-19 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-18 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-15 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-14 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-13 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-12 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-11 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-08 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-07 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-06 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-05-04 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-30 | C- | 1/5 | 1/5 | 1/5 | 1/5 | 3/5 | 1/5 | 1/5 |
| 2026-04-29 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-28 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-27 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-24 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-23 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-22 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-21 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-20 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-17 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
| 2026-04-16 | D+ | 1/5 | 1/5 | 1/5 | 1/5 | 2/5 | 1/5 | 1/5 |
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
| # | ETF | Weight | Est. AUM exposure | TER |
|---|---|---|---|---|
| 1 | Kodex Biotech 244580.KS | 1.52% | 2.18M | 0.45% |
| 2 | Kodex Healthcare 266420.KS | 0.43% | 196.4K | 0.09% |
| 3 | Kodex KOSDAQ 150 229200.KS | 0.36% | 10.85M | 0.25% |
| 4 | SAMSUNG KODEX KOSDAQ150 LEVERAGE ETF 233740.KS | 0.11% | 2.50M | 0.64% |
| 5 | Kodex KRX300 292190.KS | 0.03% | 15.4K | 0.05% |
| 6 | Kodex MSCI Momentum 275280.KS | 0.02% | 6.2K | 0.30% |
| 7 | iShares MSCI AC Far East ex-Japan Small Cap UCITS ETF ISFE.L | 0.02% | 17.3K | 0.74% |
| 8 | iShares MSCI Emerging Markets Small-Cap ETF EEMS | 0.02% | 66.9K | 0.72% |
| 9 | State Street SPDR MSCI Emerging Markets Small Cap UCITS ETF EMSD.L | 0.02% | 93.0K | 0.55% |
| 10 | Schwab International Small-Cap Equity ETF SCHC | 0.01% | 692.8K | 0.06% |
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive team data is not available for this company yet.
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for 358570.KQ
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.

MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
